Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Latest News about Virpax Pharmaceuticals Inc/

Recent news which mentions Virpax Pharmaceuticals Inc/

Lab Notes: AnPac dips into real estate with diversification strategy; Mineralys closes $220.8M IPO
Tickers INNO
Tags Chris Ryan Haohan Xu Commercial Real Estate
From Business Journals
Lab Notes: FMC enters into a $200M bio-acquisition; Virpax going the OTC route again
Tickers INNO
Tags Immunome Inc/ FMC Corporation Medical Devices
From Business Journals
Lab Notes: Endo acquires 6 product candidates for $35M; NiKang signs deal worth up to $218M
Tickers INNO
Tags Roundup Mel Sorensen Galera Therapeutics Inc/
From Business Journals
Lab Notes: Helius launches flagship product in U.S.; Virpax reports positive preclinical results for seizure drug
Tickers INNO
Tags Helius Medical Technologies Inc/ (DE) Joseph Truitt Roundup
From Business Journals
Virpax shares rise on expanded licensing deal for experimental drug
Tags Pharmaceuticals Anthony P/ Mack Biotech
From Business Journals
Lab Notes: LIMR awarded research grant; Virpax posts positive study results for pain treatment
Tickers INNO
Tags Pharmaceuticals Anthony P/ Mack Biotech
From Business Journals
Lab Notes: Lannett files FDA application for new drug; Virpax to start clinical trial for knee pain drug candidate
Tickers INNO
Tags Lannett Co/ Inc/ Anthony Mack Virpax Pharmaceuticals Inc/
From Business Journals
Lab Notes: Arbutus and Penn make headway on Covid-19 treatments; Carisma partners with Merck
Tickers INNO
Tags Saar Gill Roundup Carisma Therapeutics
From Business Journals
Lab notes: Incyte gets two FDA approvals, Coriell gets $12.4M research grant, and more
Tickers INNO
Tags Virpax Pharmaceuticals Inc/ Meenhard Herlyn Virpax Pharmaceuticals
From Business Journals
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.